Impact of Government Policies and Proposals on Community Oncologists
b"The federal government has been releasing a number of policies and proposals that will affect care delivery and are aimed at rising costs of care and prescription drugs.\\n\\nTed Okon, executive director of the Community Oncology Alliance (COA), sat down with Managed Care Cast to discuss a number of policies affecting COA\\u2019s members, including proposals around chimeric antigen receptor T-cell therapies, pharmacy benefit managers, and the Oncology Care Model.\\n\\nRead more about the stories in this podcast:\\nCMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy: https://www.ajmc.com/newsroom/cms-proposes-that-patients-be-enrolled-in-studies-to-get-coverage-for-car-tcell-therapy\\nTed Okon on Policy Priorities for COA in 2019: https://www.ajmc.com/conferences/coapayersummit2018/ted-okon-on-policy-priorities-for-coa-in-2019\\nCOA's OCM 2.0: Moving Toward a Universal Payment Model: https://www.ajmc.com/conferences/coapayersummit2018/coas-ocm-20-moving-toward-a-universal-payment-model\\nMore Than 300 Groups Seek Halt to CMS' Plans for Global Drug Pricing Index: https://www.ajmc.com/newsroom/more-than-300-groups-seek-halt-to-cms-plans-for-global-drug-pricing-index\\nTrump Proposes Allowing Medicare to Base Drug Prices on What Other Countries Pay: https://www.ajmc.com/newsroom/trump-proposes-allowing-medicare-to-base-drug-prices-on-what-other-countries-pay\\nHHS Proposes to End Drug Rebates in Medicare, Medicaid Managed Care: https://www.ajmc.com/newsroom/hhs-proposes-to-end-drug-rebates-in-medicare-medicaid-managed-care"